NCT06855823View on ClinicalTrials.gov

A Phase I/II Study of Golidocitinib Combined with Pomalidomide in R/R PTCL

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

January 14, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions
Relapsed/Refractory Peripheral T-Cell Lymphoma (R/R PTCL)
Interventions
DRUG

Golicitinib combined with Pomadomide

golidoctinib 150 mgqd, pomalidomide 2mg/3mg/4mgqd

Trial Locations (1)

510060

RECRUITING

Sun Yat-sen University Cancer Center, Guangzhou

All Listed Sponsors
lead

Sun Yat-sen University

OTHER